Analyst consensus rating
Spero Therapeutics Analyst Rating: none
Direct answer
Spero Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.00.
Forecast evidence checked October 6, 2026.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.16
- Average price target
- $5.00
- High price target
- $6.00
- Low price target
- $4.00
- Low target gap
- +244.8%
- Target upside
- +331%
- High target gap
- +417.2%
- Target range width
- 172.4%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- October 6, 2026
- Valid through
- October 13, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Spero Therapeutics?
Spero Therapeutics has a verified none consensus. The same dataset has an average price target of $5.00.
How far are Spero Therapeutics's low and high targets from the recorded price?
The low target implies +244.8%, while the high target implies +417.2%.
How many analysts are included in Spero Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Spero Therapeutics's target upside or downside calculated?
The average target of $5.00 is divided by the recorded price of $1.16, then one is subtracted to produce +331%. This does not guarantee a future return.
When was Spero Therapeutics's analyst forecast verified?
The data was verified on 2026-10-06. The dataset is valid through 2026-10-13.